ImmunoCellular cut in half as ICT-107 misses primary OS endpoint

|About: ImmunoCellular Therapeutics... (IMUC)|By:, SA News Editor

ImmunoCellular (IMUC) collapses 50% AH.

The company is out with results from a Phase 2 study of ICT-107 in newly diagnosed glioblastoma multiforme.

ICT-107 showed statistically significant PFS superiority over placebo. K-M curves (entire sample of 124 patients): Favors ICT-107; HR of 0.56; p=0.014; median PFS increase was two months. K-M curves (per-protocol population): Favors ICT-107; HR of 0.53; p=0.0074; median PFS increase was three months.

OS K-M curves fail to hit statistical significance. OS was the primary endpoint. Summary (intent-to-treat): HR of 0.87; p=0.58. Summary (per-protocol): HR of 0.79; p=0.40.

For more, see here.